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Objective. To investigate the relationship between anti–citrullinated protein antibodies (ACPAs), specific ACPA 
subspecificities, rheumatoid factor (RF) isotypes, and incident cardiovascular (CV) events in patients with rheumatoid 
arthritis (RA).
Methods. Serum samples from Swedish patients with new- onset RA (diagnosed within 1 year of symptom onset 
between 1996 and 2009) were centrally typed for anti–cyclic citrullinated peptide 2 (anti- CCP2) antibodies, 20 ACPA 
subspecificities, and RF isotypes. Patients were followed up longitudinally in nationwide registers to monitor the 
occurrence of acute coronary syndrome (ACS), stroke, CV- related death, and major adverse CV events (MACE). The 
association between each serologic marker and CV outcome, and the impact of adjustment for the Disease Activity 
Score in 28 joints (DAS28), smoking status, and income at baseline, were assessed using Cox proportional hazards 
models. In addition, associations of serologic markers with all- cause mortality were explored.
Results. In total, 2,814 patients with RA were included in the study. The median follow- up was 13 years, during 
which the CV end points of ACS, stroke, or CV- related death were reported to occur in 375 patients. Occurrence and/
or levels of anti- CCP2 were associated with risk of incident ACS (hazard ratio [HR] 1.46, 95% confidence interval 
[95% CI] 1.03–2.06), stroke (HR 1.47, 95% CI 1.03–2.10), CV- related death (P = 0.024 for association with anti- CCP2 
levels), and MACE (HR 1.34, 95% CI 1.06–1.70). Similarly, an association with the number of ACPA subspecificities 
was observed; however, this could not be attributed to any individual or group of ACPA subspecificities. Presence of 
IgM- RF was associated with all CV end points except ACS, and IgA- RF was exclusively associated with CV- related 
death. Adjustment for smoking status, income, and DAS28 scores decreased most of the HRs, whereas IgA- RF 
remained associated with CV- related death (HR 1.61, 95% CI 1.05–2.48). All of the assessed serologic makers were 
associated with all- cause mortality.
Conclusion. RF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels 
and number of subspecificities seem more important than the occurrence of particular subspecificities, and these 
associations were not explained by a history of ever smoking.
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INTRODUCTION
Patients with rheumatoid arthritis (RA) are at increased risk 
of cardiovascular (CV) disease (1). We and others have demon-
strated a rapid increase in the risk of CV events (2,3), in particu-
lar acute coronary syndromes (ACS) (4) but also stroke (5) and 
CV mortality (6), from no elevation (7) to an already elevated risk 
(8) following RA diagnosis. Although the underlying risk of CV 
events in patients with RA, as well as in the general popula-
tion, has declined during recent years, the risk of CV events in 
patients diagnosed as having RA remains elevated (4).
The increased risk of CV events in RA cannot be fully attrib-
uted to traditional CV risk factors (9), a finding that points to the 
potential role of risk factors associated with RA (10) or to a shared 
etiology between RA and CV disease (11). In terms of risk factors 
for CV events in inception cohorts of patients with RA, we and 
others have reported an association not only with accrued RA dis-
ease activity (12,13) but also with high levels of anti–citrullinated 
protein antibodies (ACPAs) and risk of ACS (10). Interestingly, 
ACPAs may also be present in atherosclerotic plaques (14), rais-
ing the possibility that, beyond their role as a marker of RA- related 
inflammation, ACPAs might be linked to CV events through other 
routes. Similarly, other studies in patients with RA, as well as in 
subjects from the general population without RA, have linked the 
presence of rheumatoid factor (RF) to CV risk (15,16).
In these previous assessments, the presence and levels 
of ACPAs have been defined using the anti–cyclic citrullinated 
peptide 2 (anti- CCP2) assay. Citrullination is, however, a general 
phenomenon, and therefore it remains unclear as to whether any 
particular ACPA subspecificities, or “load” thereof (i.e., the number 
of subspecificities expressed), are particularly linked to CV events, 
and whether any association differs across the different types of 
CV events, such as coronary disease and stroke. Similarly, any 
independent role of different RF isotypes on CV events in RA has, 
to our knowledge, not been investigated.
In this study, we therefore aimed to further investigate the 
association between the presence and levels of anti- CCP2, spe-
cific ACPAs and their combinations, and RF isotypes and the risk 
of ACS, stroke, CV- related death, and a composite end point 
of major adverse CV events (MACE) in patients with RA who 
were followed up for these CV outcomes from the time of diag-
nosis. To this end, we took advantage of prospectively collected 
data from a large inception cohort of patients with RA, assessed 
serum samples using a chip- based anti- CCP2 assay (17,18), and 
utilized linkage of the patients’ data to nationwide and population- 
based registers on incident CV end points to ascertain potential 
associations between these serologic markers and CV outcomes.
PATIENTS AND METHODS
Study design and setting. The Swedish Epidemiological 
Investigation of RA (EIRA) study includes patients from the mid-
dle and southern regions of Sweden who were newly diagnosed 
as  having RA according to the American College of Rheumatol-
ogy (ACR) 1987 classification criteria for RA (19); the EIRA study 
population has been described previously (20,21). At baseline, 
with informed consent, patients contributed a blood sample and 
answered questions on a lifestyle questionnaire. From the EIRA 
cohort, we identified a cohort of patients who were newly diagnosed 
(within 1 year of symptom onset) as having RA between 1996 and 
2009, all of whom fulfilled the ACR 1987 criteria (19). As previously 
described (22), we linked this RA cohort to the following national 
Swedish registers: the National Patient Register (NPR), with informa-
tion on inpatient and specialist care in Sweden, the Cause of Death 
register, for identification of the underlying cause of death, and the 
Longitudinal Integrated Database for Health Insurance and Labour 
Market Studies (LISA), for information regarding income. We also 
used the Swedish Rheumatology Quality (SRQ) register, from which 
we retrieved information on clinical presentation at RA diagnosis, 
and covariates. These linkages used the unique personal identifica-
tion number as key. Ethics approval for this study was obtained from 
the Stockholm ethics review board (approval nos. 2015/1844- 31/2, 
2010/810- 32, 2007/889- 31/2, and 2005/1387- 31).
Serologic data. Serum samples were obtained from the 
EIRA study participants at the time of RA diagnosis. The sera were 
assessed centrally using a commercial anti- CCP2 assay from 
Eurodiagnostica. Anti- CCP2 levels were divided into categories of 
<25 arbitrary units (AU)/ml, 25 to <75 AU/ml, 75 to <1,500 AU/ml, 
and ≥1,500 AU/ml, in accordance with the manufacturer’s instruc-
tions (23), with a status of anti- CCP2 negative being defined as a 
serum level of <25 AU/ml, and anti- CCP2 high- positive as a serum 
level of ≥75 AU/ml (3 times the reference value as described in ref. 
24). Using the manufacturer’s suggested anti- CCP2 cutoff level of 
25 AU/ml, the diagnostic specificity of the anti- CCP2 assay was 
98.4% among 578 EIRA study control subjects.
ACPA subspecificities were centrally tested on a custom- 
made microarray (Thermo Fisher Scientific) (17). For the present 
analyses, a total of 20 ACPA subspecificities was included. The 
cutoff level for the subspecificities was set based on the 98th per-
centile value among 538 EIRA study general population control 
subjects (18). IgA- , IgG- , and IgM- RFs were analyzed using an EliA 
immunoassay on a Phadia 2500 instrument, using cutoff levels set 
at the 98th percentile value among the RA- free EIRA study controls.
Follow- up and outcomes. Using the NPR and Cause of 
Death registers, we obtained follow-up data on all individuals from 
the time of their inclusion in the EIRA study until a first event of 
ACS, CV- related death, stroke, or MACE, defined according to a 
hospitalization listing with a relevant International Classification of 
Diseases, Tenth Revision (ICD- 10) code (ICD- 10 codes I20.0 or 
I21 for cause of death [any ICD- 10 code listed as “I” for CV- related 
death], ICD- 10 codes I60–I64 for stroke, and any of the above 
ICD- 10 codes for MACE). Follow- up was censored at the time of 
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death, emigration, or the end of the study period (December 31, 
2016).
Statistical analysis. For the statistical analyses, we 
included all ACPA subspecificities with a frequency of ≥10% in 
our sample. We further defined autoantibody “load” as the total 
number of these subspecificities expressed by an individual, cat-
egorized into tertiles based on the distribution in our study popu-
lation. The Spearman’s rank correlation test was used to calculate 
the correlation between anti- CCP2 levels and number of specific 
autoantibodies expressed.
For each outcome, we calculated its incidence in the study 
population, and used Cox proportional hazards models to assess 
the association of each CV outcome with ACPA/RF status, num-
ber of ACPA subspecificities expressed, and anti- CCP2 antibody 
load. All models were adjusted for age, sex, and calendar period 
of RA diagnosis. For the analyses of individual subspecificities, 
we applied Bonferroni’s correction using a factor of 76 to adjust 
for multiple hypothesis testing. We excluded from the analyses 
of each particular CV end point all individuals who had a history 
of the outcome of interest prior to the start of follow- up. Where 
applicable, we did, however, adjust the analyses of each CV out-
come for a history of any of the other CV outcomes. Each ACPA 
subspecificity was analyzed in separate models.
With regard to RF, the isotypes were analyzed in sepa-
rate models. In addition, we included all RF isotypes jointly in a 
single model, and ran one model that included all 3 RF isotypes 
together with anti- CCP2 status.
Exploratory analysis. We performed exploratory analyses 
to investigate the impact of adjustment for each of 3 CV event 
determinants (smoking status, income [as a proxy for general 
socio economic status, and thus CV events], and RA disease 
activity at diagnosis) on the associations between RA- specific 
autoantibodies and the CV end points. With regard to smoking, 
we collected data on smoking status (never [reference] versus 
ever smoker) at the time of RA diagnosis as reported by each 
patient on the EIRA lifestyle questionnaire, and adjusted our main 
analyses for smoking status. With regard to anti- CCP2 status and 
RF isotypes, we also performed analyses stratified by smoking 
status.
For income, we retrieved information from the year before RA 
diagnosis from the LISA database. Data on income was adjusted 
for inflation and divided into deciles, with the highest income 
group used as reference.
For RA disease activity at diagnosis, we retrieved data (when 
available) from the SRQ registry on each patient’s Disease Activ-
ity Score in 28 joints (DAS28) at the time of RA diagnosis, and 
divided the scores into categories of low (DAS28 ≤3.2), medium 
(3.2 < DAS28 ≤ 5.1), and high (DAS28 >5.1) as reported at the 
time of the first visit, which was required to be not more than 40 
days before or 75 days after the blood sample was obtained.
To contextualize any association with the CV end points, we 
also investigated the association between the RA antibodies and 
all- cause mortality. To this end, we retrieved data from the popula-
tion register on deaths attributed to any cause.
RESULTS
Characteristics of the patients. We identified 2,814 
patients with incident RA and with information on the presence 
or absence of anti- CCP2 antibodies, specific ACPAs, and RF. 
The median age at the time of RA diagnosis was 51 years (inter-
quartile range [IQR] 18), and median follow- up from the time of 
RA diagnosis was 13 years (IQR 6.5) (Table 1). Most study partic-
ipants were born in Sweden (88%) while 9% were born in other 
European countries and 3% in other parts of the world. Among 
the 2,814 patients, 1,816 (65%) were anti- CCP2 positive and 
1,614 (57%) were IgM- RF positive.
During follow- up, we observed 147 first occurrences of ACS 
events (incidence 4.3 per 1,000 person- years), 141 first occur-
rences of stroke events (incidence 4.1 per 1,000 person- years), 
87 CV- related deaths (incidence 2.4 per 1,000 person- years), and 
313 MACE events (incidence 9.4 per 1,000 person- years).
ACPA and ACPA subspecificities. Anti- CCP2 positiv-
ity was associated with the risk of incident ACS (hazard ratio 
[HR] 1.46, 95% confidence interval [95% CI] 1.03–2.06), stroke 
(HR 1.47, 95% CI 1.03–2.10), and MACE (HR 1.34, 95% CI 
 1.06–1.70), with a similar effect size for CV- related death although 
the association was not statistically significant (HR 1.48, 95% CI 
0.94–2.31). When categorized by levels of anti- CCP2, there were 
Table 1. Demographic and clinical characteristics of the Swedish study population (n = 2,814) followed up for incident CV events from 
RA diagnosis until 2017*
ACS Stroke CV- related death MACE
No. of patients 2,814 2,814 2,814 2,814
No. with a history of the CV event in question before RA diagnosis 32 20 0 50
No. remaining for analysis after exclusion 2,782 2,794 2,814 2,764
No. (%) women 2,003 (72.0) 2,005 (71.8) 2,015 (71.6) 1,993 (72.1)
Age at RA diagnosis, median (IQR) years 51.4 (18.0) 51.4 (18.0) 51.5 (18.0) 51.3 (18.0)
Follow- up, median (IQR) years 12.3 (6.5) 12.4 (6.5) 12.6 (6.5) 12.1 (6.5)
Incidence of each CV event per 1,000 person- years 4.3 4.1 2.5 9.4
* CV = cardiovascular; RA = rheumatoid arthritis; ACS = acute coronary syndrome; MACE = major adverse cardiovascular events; IQR = 
interquartile range. 
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statistically significant trends toward increasing incidence of CV 
events (stroke, CV- related death, and MACE) with increasing anti- 
CCP2 levels, and this was borderline significant for incidence of 
ACS (Table 2).
In analyses of specific ACPA subspecificities, 17 autoanti-
bodies were found to have a prevalence of ≥10% in our sam-
ple. These included Fil 307–324 (CCP- 1), Vim 60–75, Vim 2–17, 
Fibβ 36–52, Fibα 563–583, Fibα 580–600, Eno 5–21 (CEP- 1), 
Fib α621–635, Fib α36–50, Fibβ 60–74, Ptm13, Ptm36, Pept- Z1, 
Pept- Z2, Pept- 1, Pept- 5, and Bla26. All 17 autoantibodies are 
described in more detail in ref. 18, except for Ptm13 and Ptm36, 
which are described in refs. 25 and 26 (details on the correlation 
structure are provided in Supplementary Table 1 and Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology website 
at http://onlinelibrary.wiley.com/doi/10.1002/art.41381/abstract). 
The median number of ACPA subspecificities expressed was 6 
(IQR 11). We noted borderline or statistically significant associ-
ations between the number of subspecificities expressed and 
the risk of each of the CV end points. The HRs for each CV end 
point per 1- unit increase in the number of specific ACPAs were 
as follows: for ACS, HR 1.02 (95% CI 0.99–1.05); for stroke, HR 
1.04 (95% CI 1.01–1.07); for CV- related death, HR 1.04 (95% CI 
1.00–1.08); and for MACE, HR 1.03 (95% CI 1.01–1.05) (Table 3).
Similar to the analyses of anti- CCP2 levels, we noted a trend 
toward increasing HRs for each CV end point with increasing 
autoantibody load (Table  3). The Spearman’s rank correlation 
between anti- CCP2 level and number of ACPA subspecificities 
expressed was 0.89 (P < 2.2 × 10−16).
No single ACPA subspecificity was associated with all 4 CV 
outcomes (Table 4). In analyses of the 95% CIs of each HR, only 
anti–CEP- 1 displayed a statistically significant association with 
the risk of ACS. With regard to risk of stroke, 10 subspecificities 
were significantly associated with this CV end point, with Fibβ 
60–74 having the highest HR for association (HR 1.82, 95% 
CI 1.28–2.59). With regard to CV- related death and MACE, 5 
autoantibodies and 9 autoantibodies, respectively, were signifi-
cantly associated with the risk of these CV end points. After Bon-
ferroni’s correction for multiple hypothesis testing, all of these 
associations with individual subspecificities lost their statistical 
significance.
RF isotypes. For associations of RFs with CV end points, the 
pattern was markedly different across isotypes. For IgM- RF, risk 
associations with each of the CV outcomes were of a similar mag-
nitude, but IgM- RF was significantly associated only with the risk 
of stroke (HR 1.42, 95% CI 1.01–2.01) and MACE (HR 1.40, 95% 
CI 1.11–1.76), but not with ACS (HR 1.40, 95% CI 1.00–1.96) or 
CV- related death (HR 1.47, 95% CI 0.94–2.27) (Table 4). IgA- RF 
was associated with an increased risk of CV- related death (HR 
1.88, 95% CI 1.22–2.88) (Table 4). IgG- RF was not significantly 
associated with any of the CV outcomes (Table 4).
In the model with all 3 isotypes present, all of these associ-
ations with CV outcomes remained, but when anti- CCP2 status 
was included in the model, all associations (with the RF isotypes 
as well as with anti- CCP2) disappeared, except the association 
between IgA- RF and CV- related death (HR 1.92, 95% CI 1.04–
3.56).
Results of exploratory analysis. All but 9 individuals 
had provided information about smoking habits at the time of RA 
diagnosis. When estimating the sex- and age- adjusted mortality 
rates for smokers and nonsmokers in the antibody- positive and 
antibody- negative groups, we observed that the high relative risks 
of CV- related death associated with IgA- RF and IgG- RF were 
attributable to the very low CV- related death rates observed in 
RF- negative never smokers (compared to the total incidence of 
CV- related deaths of 2.5 per 1,000 person- years) (Table  1). In 
the IgG- RF–negative patients who were never smokers, the rate 
of CV- related deaths was 0.40 (95% CI 0.08–1.17) per 1,000 
person- years, and in IgA- RF–negative patients who were never 
smokers, it was 0.44 (95% CI 0.09–1.30) per 1,000 person- years 
(see Supplementary Table 3, available on the Arthritis & Rheu-
matology website at http://onlinelibrary.wiley.com/doi/10.1002/
art.41381/abstract).
With regard to associations with the presence and/or titers 
of anti- CCP2, when analyses were adjusted for smoking status, 
the observed univariate associations with anti- CCP2 lost their sta-
tistical significance. In analyses stratified by both anti- CCP2 and 
smoking status, the only association remaining was between anti- 
CCP2 and risk of ACS (HR 1.51, 95% CI 1.01–2.27) among ever 
smokers.
With regard to associations with the RF isotypes, adjustment 
for smoking led to a decrease in the strength of all associations, 
but the association between IgA- RF and CV- related death (HR 
1.61, 95% CI 1.05–2.48), and between IgM- RF and MACE (HR 
1.28, 95% CI 1.01–1.62) remained significantly increased. In 
analyses stratified by smoking status, we observed associations 
between IgA- RF and IgG- RF and CV- related death and between 
IgG- RF and IgM- RF and MACE, among never smokers (see Sup-
plementary Table 2, available on the Arthritis & Rheumatology 
website at http://onlinelibrary.wiley.com/doi/10.1002/art.41381/
abstract). With regard to CV- related death among never smok-
ers, these associations were notably elevated (for association with 
IgA- RF, HR 3.88, 95% CI 1.04–14.54; for association with IgG- RF, 
HR 6.29, 95% CI 1.63–24.25).
With regard to associations with most of the ACPA subspe-
cificities, adjustment for smoking led to a decrease in the HRs. 
However, for the risk of CV- related death, the HRs for several 
autoantibodies were elevated. Nevertheless, similar to that in 
the main analysis, the statistical significance of these associations 
was lost following Bonferroni’s correction.
In total, 1,762 individuals (63%) had information on smok-
ing, income, and initial RA disease activity. Smoking was itself 
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associated with all CV- related outcomes except ACS. Income 
level, but not the initial DAS28 value, was associated with all out-
comes except stroke. In this patient subset of 1,762 patients, the 
observed overall associations with anti- CCP2 positivity, the trends 
toward association with anti- CCP2 levels, the ACPA autoantibody 
load, and the trends toward associations with ACPA autoantibody 
load all remained notable or were accentuated in comparison 
to the associations observed in analyses of the entire cohort of 
2,814 patients. Adjustment of these analyses for smoking status, 
income level, and DAS28 scores only slightly shifted the HRs, 
although the statistical significance of some of the trends was lost 
in this subset of patients comprising 63% of the original popu-
lation. With regard to IgA- RF, the HR for CV- related death was 
2.65 (95% CI 1.51–4.63), and this association remained signifi-
cant when smoking status, income level, and DAS28 scores were 
included in the model (HR 2.35, 95% CI 1.34–4.14) and also when 
the model was adjusted for anti- CCP2 status (HR 2.87, 95% CI 
1.19–6.93). Results of all of these analyses are shown in Supple-
mentary Tables 4, 5, 6, and 7, available on the Arthritis & Rheu-
matology website at http://onlinelibrary.wiley.com/doi/10.1002/
art.41381/abstract.
When the outcome was changed to all- cause mortality, we 
noted strong associations with anti- CCP2 positivity, anti- CCP2 
level, autoantibody load, most of the ACPA subspecificities, and 
each RF isotype (see Supplementary Table 8, available on the 
Arthritis & Rheumatology website at http://onlinelibrary.wiley.com/
doi/10.1002/art.41381/abstract).
DISCUSSION
We investigated the association between ACPA positivity 
and levels, ACPA subspecificities, RF isotypes, and incident CV 
events in a large and prospectively monitored inception cohort 
of patients with RA. We made the following important observa-
tions: 1) ACPA (anti- CCP2) positivity in RA is a marker for several 
CV end points. 2) These associations trended toward an asso-
ciation with higher anti- CCP2 levels. 3) A trend of association of 
the CV end points with increasing number of ACPA subspecif-
icities expressed was also evident. 4) Whereas many individual 
ACPAs were associated with the CV end points, there was no 
clear pattern of particularly strong associations with any par-
ticular ACPA, at least not consistently so within specific groups 
of ACPAs targeting citrullinated epitopes in individual proteins 
across CV end points. 5) Presence of RF was associated with 
CV event risk, but the associations differed across the RF iso-
types, with IgM- RF being associated with stroke and MACE, but 
IgA- RF being linked to CV- related mortality. 6) Finally, we noted 
that for most of the autoantibodies, the associations decreased 
or disappeared when the analyses were adjusted for smoking 
status, initial RA disease activity, and socioeconomic status, 
whereas with regard to IgA- RF, the association with CV- related 
death remained.
With regard to ACPA positivity per se, our results corrob-
orate but also extend those of previous studies on RA sero-
logic markers and RA outcomes. For instance, Ajeganova et al 
com pared the association between the presence of anti- CCP2 
or RF and mortality across 3 RA cohorts, and found associations 
with CV- related mortality with an effect size similar to ours 
(27). In our present study, we expanded these findings by also 
assessing the levels of anti- CCP2, as well as 17 different ACPA 
subspecificities and IgA- and IgG- RF. We further demonstrated 
that the associations of these autoantibodies applied across 
several CV clinical fatal or nonfatal phenotypes, rather than 
being merely markers of increased overall mortality (which is also 
a recognized role of these autoantibodies, as demonstrated by 
our exploratory analyses).
In contrast to previous studies, we further investigated dif-
ferent subspecificities of ACPAs. The mechanistic and pathologic 
roles of the different subspecificities are unclear, and our epidemi-
ologic investigation was not designed to address such questions. 
Interestingly, a previous report on citrullinated antibodies and asso-
ciations with atherosclerotic plaques in early RA (14) found the 
presence of both citrullinated vimentin and citrullinated fibrinogen 
in the plaques, as well as an association between the presence of 
anticitrullinated vimentin and fibrinogen antibodies and increased 
plaque burden. We aimed to elucidate whether any particular sub-
specificity carried a greater risk, indicating that it might be more 
causally involved, but such attempts are difficult to design and 
interpret, and we fully acknowledge the complexity of the data, with 
the intricate structure of co- reactivity and potential cross- reactivity 
between the different ACPA subspecificities. Although we did find 
that many subspecificities were associated with different types of 
CV end points, subspecificities targeting a specific protein were 
never associated with the same outcome. What seemed more 
important, and remained consistent in the exploratory analysis, 
was the number of subspecificities expressed, which is also con-
sistent with the observation of a strong correlation between anti- 
CCP2 level and number of subspecificities expressed.
With regard to RF, several reports have described an asso-
ciation with overall mortality (28–30), overall CV mortality (27,30), 
and with certain CV phenotypes (31) in RA, which has also been 
the case in the general (non- RA) population (15,16). Our results 
corroborate (with respect to RF overall) and extend (with respect 
to isotype- specific results) these findings. It should be noted, 
though, that the previously reported associations between RF and 
CV disease in the general population are difficult to interpret, as the 
prevalence of RF in both of the existing studies were higher than 
expected (15,16). This might be attributable to the only existing 
instruction denoting a cutoff level for RA- associated autoanti-
bodies, the open- ended cutoff of >95% specificity for RF 
described in the ACR 1987 classification criteria for RA (19). For 
ACPAs, including anti- CCP2, no parallel directions exist, and cut-
off levels in fact vary more than 500% between different commer-
cial tests (see Table  2 in ref. 32). For that reason, we carefully 
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adjusted all autoantibody cutoff levels to the 98th percentile, which 
is close to the 98.4% specificity for anti- CCP2 in the EIRA study. 
Our study thus further extends the results by demonstrating how 
these associations vary across RF isotypes, where IgM- RF was 
associated with several CV disease types, but IgA- RF was more 
distinctly associated with CV- related mortality. One explanation 
could be that an association between IgA- RF and extraarticu-
lar manifestations was previously observed in patients with RA 
(33), whose mortality rate was increased and in whom CV events 
were the main cause of death (34).
Our study has some limitations. Because of missing data, the 
subset of patients studied, in which adjustments could be made 
for smoking status and other risk factors, was smaller than the 
original study population (but displayed very similar associations). 
We further had limited means to adjust for certain CV risk factors 
such as lipid profile, family history of CV disease, physical activ-
ity, and certain comorbid conditions, such as hypothyroidism, 
which, by themselves, may or may not affect CV risk. We also 
did not have data to address the impact of the disease course 
on the outcomes. Instead, we designed our study to investigate 
the association between serologic status at baseline and CV 
outcomes.
Strengths of our study include the identification of, and pro-
spective, complete, and independent follow- up of a large cohort 
of patients newly diagnosed as having RA (the largest studied 
so far among studies of fine specificities and CV outcomes in 
patients with RA) who were treated in rheumatology clinics 
according to standard treatment guidelines. Our CV end points 
were all based on validated and robust definitions. Moreover, 
we were able to centrally analyze the serum samples obtained 
at baseline, thereby minimizing interassay/interreader variabil-
ity, selection bias, or reversed causality. In addition, we could 
assess the potential impact of certain additional CV risk factors, 
although the size of the study and the time period covered pre-
vented accurate identification of additional risk factors, such as 
diabetes, across the entire RA cohort. Because of the robustness 
of the data, we also believe our findings to be generalizable to 
other countries.
From a clinical perspective, our data imply that patients with 
seronegative RA are at a lower risk of CV events, while patients 
with high anti- CCP2 levels or presence of IgA- or IgG- RF at diag-
nosis are at higher risk and might benefit from closer monitoring 
from a cardio- preventative perspective. In this regard, specific 
ACPA subspecificities offer no further predictive capacity.
In conclusion, patients with RA who are seropositive for 
ACPAs and RF carry a risk of several types of CV end points, 
including CV- related and overall mortality, which is independent of 
a history of ever smoking. These associations do not seem to be 
driven by any specific (pattern of) ACPAs, suggesting that for CV 
comorbidities in RA, autoantibody load may be more important 
than individual ACPAs. For RF, the risks of CV events seem to vary 
across RF isotypes.
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